At WCLC 2026 in Seoul, Republic of Korea, Stephen Liu discusses whether PD-1/VEGF bispecific antibodies could improve treatment outcomes in advanced lung cancer, with a focus on cooperative binding, early clinical signals, safety, biomarkers, resistance, and future combinations.
Stephen Liu, MD, is Director of Thoracic Oncology and Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center. Stephen Liu is also an Associate Professor of Medicine at Georgetown University and a board-certified medical oncologist.
Organized by the International Association for the Study of Lung Cancer, WCLC 2026 took place from September 12 to 15. In this interview, Stephen Liu discusses the potential rationale for combining PD-1 pathway inhibition with VEGF blockade in a single bispecific molecule and the clinical questions that remain as this approach moves through development.
Key highlights from this clip:
● Why combining PD-1 pathway inhibition with VEGF blockade may offer a distinct treatment rationale in advanced lung cancer
● How one bispecific molecule may support consistent pharmacokinetic delivery and cooperative binding between the two targeting functions
● Early clinical results discussed in the interview, including progression-free survival and overall survival signals in non-small cell lung cancer
● The potential relevance of these agents in squamous lung cancer, where bleeding risk has historically complicated VEGF blockade
● Why biomarkers, patient selection, safety, and resistance remain central challenges for clinical translation
● Future priorities including global studies across PD-L1 subgroups and histologies, regulatory evidence generation, and combinations with chemotherapy or antibody-drug conjugates
This video is intended for medical education and professional discussion.